Authors
Latest:
How Digital Twins are Driving Sustainability in Clinical Supply PlanningEmerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.
Latest:
3 Common eCOA Implementation Challenges and How to Solve ThemOvercoming hurdles with licensing complexities, post-production changes, and IRB submissions can help in reducing timelines and increasing collaboration.
Latest:
Smart New Normal in Medication Management—Personalized, Integrated, and FlexibleWhat the next generation medication management in clinical trials should entail and insights on smart technologies and synergistic partnerships—backed by real-life implementation use cases.
Latest:
Optimizing Patient Recruitment and Engagement StrategiesFive strategies to reduce risk and achieve deadlines.
Latest:
Establishing Metrics and Standardization for Non-CRF Data in EDCWhile Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
Latest:
A New Era in Clinical TrialsIndustry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.
Latest:
Artificial Intelligence Drives Industry Response to Project OptimusThe FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Latest:
Case Study: Successful System Integration for Decentralized Clinical Trials endpoint Clinical and THREAD’s Solution Ensures the Successful Flow of eConsent DataToday’s clinical studies are increasingly complex and require patient-centric trial designs, like decentralized trials, more than ever before. As trials incorporate more decentralized components there is an ever-present need for multiple system integrations to support the various trial functions, with the goal being that all trial data flows seamlessly between systems and is stored in one repository for efficient oversight and analysis. These numerous integrated systems require closely managed integration, synchronization, and supportive partnerships to minimize error and maximize efficiency. In this case study, partners endpoint and THREAD dig-in to explore how IRT can be integrated with decentralized clinical trial (DCT) technology, working through tightly integrated workflows, to provide a streamlined process, a better user experience for Sites and Participants, higher quality data and real-time access to information.
Latest:
AI/ML Approaches to Assisted Medical Writing—Part 2Following a discussion around summarization in Part 1, Part 2 discusses the method of pure abstraction in light of recent advances in deep learning and AI.
Latest:
Best Practices in Managing CGT From Protocol Design to Data ManagementThough the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge.
Latest:
Understanding Acceptability of eConsent from a Global, Ethical, and Industry PerspectiveUsing surveys to collect various viewpoints on eConsent from ethics, sponsors, and vendors.
Latest:
The State of the Clinical Trial Site Technology Industry: Examining Key TrendsFindings from Florence Healthcare’s State of Clinical Trial Technology Industry survey about how clinical operations technology changed in 2020 and how they expected it to evolve throughout this year.
Latest:
How Automation and Generative AI will Transform Clinical Trials in the Next 1-2 YearsDCTs, data, and analytics are all areas that could be impacted in the near future.
Latest:
Four Strategic Considerations to Choose an EDCCompanies share their experience in future-proofing clinical data technology.
Latest:
The Future of Personalized Medicine Hinges on Revolutionizing Business ModelsThe era of big pharma as product-first companies must end, as services become the larger priority.
Latest:
Spontaneous Reporting System for Adverse Drug Reactions in GermanyWhile underreported, ADR data offers significant value to the drug development value chain to refine the predictive capability and stability, and provide enhanced patient safety.
Latest:
Patient-Centered Recruitment and RetentionBy decentralizing trials whenever feasible, sites can decrease patient burden, clinops workload, and the number of on-site participants.
Latest:
eSource Interoperability Between EHR and EDCEvidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Latest:
AI to Impact Clinical Trials and Manufacturing in Life SciencesArtificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.
Latest:
Navigating a Decentralized Trial Model and the Changing Clinical Landscape During COVID-19A top-down analysis of the decentralized trial model’s benefits and impact on the industry.
Latest:
Where Innovation and Patients Meet to Improve Cancer CarePromising scientific advances are pacing oncology drug development.
Latest:
COVID-19 Pandemic Exemplifies the Benefits of CROsThe adaptability and innovative capacity of CROs highlighted in EUCROF survey.
Latest:
Enabling Evidence-Based Study Endpoint SelectionHarnessing advances in digital health technologies for a more precision-measured approach.
Latest:
Using Real-World Data in Patient RecruitmentGrowing availability of RWD leads new drug development process.
Latest:
Righting the Ship in 2024 and Beyond: Navigating the First Extended Workforce Recession in the History of the Life Sciences IndustryWebinar Date/Time: Tue, Tue, Nov 28, 2023 11:00 AM EST
Latest:
COVID-19 and Its Impact on the Future of Clinical Trial ExecutionFindings from a Tufts study examining the effects of COVID-19 on clinical trials.
Latest:
FDA Finalizes Decentralized Clinical Trial GuidanceThe FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Latest:
Addressing Population Gaps in Therapy Adoption: Using Real-World Data to Bridge the Clinical Trial DivideHow clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.
